Table 7.

The relationship between SLC30A family genes and OS in treatment methods of GC patients (Kaplan–Meier Plotter).

	Treatment	Cases	HR (95% CI)	P-value
SLC30A1	Surgery alone	380	0.79 (0.59–1.06)	0.1190
	5 FU based adjuvant	34	2.29 (0.75–6.99)	0.1360
	Other adjuvant	76	0.28 (0.12–0.69)	0.0030*
SLC30A2	Surgery alone	380	1.65 (1.16–2.35)	0.0051*
	5 FU based adjuvant	34	0.3 (0.1–0.9)	0.0230*
	Other adjuvant	76	0.61 (0.25–1.49)	0.2700
SLC30A3	Surgery alone	380	1.47 (1.03–2.08)	0.0300*
	5 FU based adjuvant	34	1.99 (1.34–2.95)	0.0005*
	Other adjuvant	76	2.47 (1.02–5.96)	0.0380*
SLC30A4	Surgery alone	380	1.26 (0.93–1.7)	0.1340
	5 FU based adjuvant	34	0.42 (0.16–1.08)	0.0630
	Other adjuvant	76	2.08 (0.87–5)	0.0940
SLC30A5	Surgery alone	380	0.72 (0.54–0.97)	0.0300*
	5 FU based adjuvant	34	2.22 (0.51–9.66)	0.2750
	Other adjuvant	76	0.41 (0.14–1.21)	0.0950
SLC30A6	Surgery alone	380	0.74 (0.56–0.99)	0.0450*
	5 FU based adjuvant	34	0.71 (0.29–1.75)	0.4520
	Other adjuvant	76	1.56 (0.57–4.3)	0.3810
SLC30A7	Surgery alone	380	0.69 (0.51–0.91)	0.0098*
	5 FU based adjuvant	34	0.55 (0.22–1.37)	0.1930
	Other adjuvant	76	0.3 (0.12–0.75)	0.0060*
SLC30A8	Surgery alone	380	1.69 (1.25–2.3)	0.0006*
	5 FU based adjuvant	34	3.17 (1.23–8.16)	0.0120*
	Other adjuvant	76	2.17 (0.89–5.31)	0.0830
SLC30A9	Surgery alone	380	0.68 (0.51–0.91)	0.0085*
	5 FU based adjuvant	34	0.55 (0.38–0.79)	0.0010*
	Other adjuvant	76	0.08 (0.01–0.56)	0.0010*
SLC30A10	Surgery alone	380	1.31 (0.93–1.85)	0.1234
	5 FU based adjuvant	34	1.61 (1.14–2.28)	0.0067*
	Other adjuvant	76	0.17 (0.04–0.75)	0.0081*

a: The P-value was set at 0.05 and the * indicate that the results are statistically significant.

b: FU, fluorouracil.